NovoSeven® RT comes in compact packaging, and is room temperature stable up to 77°F, so you can be on the go.a
Experience proven bleed control.
Data from a randomized, double-blind study of patients with hemophilia A and B with and without inhibitors.
Also proven effective in the adept™2 study, one of the largest clinical trials conducted in patients with hemophilia with inhibitors.
Joint, target joint, skin, and mucous membrane, muscle, and other bleeding episodes (n=227 bleeding episodes)
Room temperature stable and travel ready.
Quick to mix.b
NovoSeven® RT with MixPro® makes mixing a dose fast. The prefilled syringe means no extra steps to fill a syringe with diluent.
After mixing, NovoSeven® RT may be stored at room temperature in the vial for up to 3 hours.
bCompared to mixing using histidine vials.
Fast to infuse.
Faster infusion means NovoSeven® RT gets to work stopping bleeds more quickly.
- NovoSeven® RT is up to 18x faster to infuse than FEIBAc-e
- Infusing takes 2 to 5 minutes
cAdminister as a slow bolus injection over 2 to 5 minutes, depending on the dose administered.
dIndividual doses are compared and based on an 88-kg (194-lb) person.
ePatients are cautioned that the maximum injection or infusion rate must not exceed 2 units per kilogram of body weight per minute.
Fast bleed control.
Helps control joint bleeds in as few as 5 hours with a median of 2 doses.f
- NovoSeven® RT can be redosed every 2 hours,c which lets you dose as needed to get bleeds under control fast
- Your hemophilia treatment center (HTC) and your doctor will help you decide which dosing schedule is best for you
fBased on individual dosage for joint bleeds in people with hemophilia A or B with and without inhibitors.
Established safety profile that comes from experience.g
In clinical trials of NovoSeven® RT, a low rate of blood clots (0.2%) were reported.h And NovoSeven® RT is made without any human blood or plasma. It’s the only FDA-approved recombinant bypassing agent for hemophilia with inhibitors. Recombinant manufacturing minimizes the possibility of viral contamination.
NovoSeven® RT has only 1 main component.
What if I need surgery or a procedure?
We understand that you have concerns about controlling bleeds if you ever need surgery or a procedure. The good news is that NovoSeven® RT is approved by the FDA for treating people with hemophilia A or B with inhibitors during and after surgery and procedures.
In fact, in a clinical trial, NovoSeven® RT was proven to effectively control bleeds throughout the surgical process. Here are the results:
Talk with your doctor for more information on controlling bleeds during and after surgery or procedures.
What about surgery and procedures?
Approved for surgical use and procedures for patients with hemophilia A or B with inhibitors.
Hear a patient's story.
Meet Justin. NovoSeven® RT fits in when he's living life on the go.